Identification of Baicalin As an Immunoregulatory Compound by Controlling T(H)17 Cell Differentiation

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 Mar 2

PMID 21359178

Citations 27

Authors

Ji Yang

Xue Yang

Yiwei Chu

Ming Li

Affiliations

Soon will be listed here.

Abstract

T(H)17 cells have been implicated in a growing list of inflammatory disorders. Antagonism of T(H)17 cells can be used for the treatment of inflammatory injury. Currently, very little is known about the natural compound controlling the differentiation of T(H)17 cells. Here, we showed that Baicalin, a compound isolated from a Chinese herb, inhibited T(H)17 cell differentiation both in vitro and in vivo. Baicalin might inhibit newly generated T(H)17 cells via reducing RORγt expression, and together with up-regulating Foxp3 expression to suppress RORγt-mediated IL-17 expression in established T(H)17 cells. In vivo treatment with Baicalin could inhibit T(H)17 cell differentiation, restrain T(H)17 cells infiltration into kidney, and protect MRL/lpr mice against nephritis. Our findings not only demonstrate that Baicalin could control T(H)17 cell differentiation but also suggest that Baicalin might be a promising therapeutic agent for the treatment of T(H)17 cells-mediated inflammatory diseases.

Citing Articles

Immuno-modulatory role of baicalin in atherosclerosis prevention and treatment: current scenario and future directions.

Wang L, Huang S, Liang X, Zhou J, Han Y, He J Front Immunol. 2024; 15:1377470.

PMID: 38698839 PMC: 11063305. DOI: 10.3389/fimmu.2024.1377470.

Polyphenols: immunonutrients tipping the balance of immunometabolism in chronic diseases.

Ferreira C, Vieira P, Sa H, Malva J, Castelo-Branco M, Reis F Front Immunol. 2024; 15:1360065.

PMID: 38558823 PMC: 10978763. DOI: 10.3389/fimmu.2024.1360065.

Baricitinib relieves DSS-induced ulcerative colitis in mice by suppressing the NF-κB and JAK2/STAT3 signalling pathways.

Wu Q, Liu Y, Liang J, Dai A, Du B, Xi X Inflammopharmacology. 2024; 32(1):849-861.

PMID: 38227095 DOI: 10.1007/s10787-023-01396-6.

Harnessing the power of traditional Chinese medicine monomers and compound prescriptions to boost cancer immunotherapy.

Miao K, Liu W, Xu J, Qian Z, Zhang Q Front Immunol. 2023; 14:1277243.

PMID: 38035069 PMC: 10684919. DOI: 10.3389/fimmu.2023.1277243.

The Pharmacological Efficacy of Baicalin in Inflammatory Diseases.

Wen Y, Wang Y, Zhao C, Zhao B, Wang J Int J Mol Sci. 2023; 24(11).

PMID: 37298268 PMC: 10253382. DOI: 10.3390/ijms24119317.

References

Xiao S, Jin H, Korn T, Liu S, Oukka M, Lim B . Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J Immunol. 2008; 181(4):2277-84. PMC: 2722959. DOI: 10.4049/jimmunol.181.4.2277. View

Park H, Li Z, Yang X, Chang S, Nurieva R, Wang Y . A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005; 6(11):1133-41. PMC: 1618871. DOI: 10.1038/ni1261. View

Steinmetz O, Turner J, Paust H, Lindner M, Peters A, Heiss K . CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis. J Immunol. 2009; 183(7):4693-704. DOI: 10.4049/jimmunol.0802626. View

Reboldi A, Coisne C, Baumjohann D, Benvenuto F, Bottinelli D, Lira S . C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol. 2009; 10(5):514-23. DOI: 10.1038/ni.1716. View

Zeng Y, Song C, Ding X, Ji X, Yi L, Zhu K . Baicalin reduces the severity of experimental autoimmune encephalomyelitis. Braz J Med Biol Res. 2007; 40(7):1003-10. DOI: 10.1590/s0100-879x2006005000115. View

Louten J, Boniface K, De Waal Malefyt R . Development and function of TH17 cells in health and disease. J Allergy Clin Immunol. 2009; 123(5):1004-11. DOI: 10.1016/j.jaci.2009.04.003. View

Nistala K, Moncrieffe H, Newton K, Varsani H, Hunter P, Wedderburn L . Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum. 2008; 58(3):875-87. PMC: 2675006. DOI: 10.1002/art.23291. View

Intlekofer A, Banerjee A, Takemoto N, Gordon S, DeJong C, Shin H . Anomalous type 17 response to viral infection by CD8+ T cells lacking T-bet and eomesodermin. Science. 2008; 321(5887):408-11. PMC: 2807624. DOI: 10.1126/science.1159806. View

Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, Sugimoto N . Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med. 2007; 204(12):2803-12. PMC: 2118525. DOI: 10.1084/jem.20071397. View

10.

Shibata K, Yamada H, Hara H, Kishihara K, Yoshikai Y . Resident Vdelta1+ gammadelta T cells control early infiltration of neutrophils after Escherichia coli infection via IL-17 production. J Immunol. 2007; 178(7):4466-72. DOI: 10.4049/jimmunol.178.7.4466. View

11.

Zheng Y, Danilenko D, Valdez P, Kasman I, Eastham-Anderson J, Wu J . Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2006; 445(7128):648-51. DOI: 10.1038/nature05505. View

12.

Ye P, Rodriguez F, Kanaly S, Stocking K, Schurr J, Schwarzenberger P . Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med. 2001; 194(4):519-27. PMC: 2193502. DOI: 10.1084/jem.194.4.519. View

13.

Wong C, Ho C, Li E, Lam C . Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus. 2000; 9(8):589-93. DOI: 10.1191/096120300678828703. View

14.

Rachitskaya A, Hansen A, Horai R, Li Z, Villasmil R, Luger D . Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J Immunol. 2008; 180(8):5167-71. PMC: 2442579. DOI: 10.4049/jimmunol.180.8.5167. View

15.

Bettelli E, Carrier Y, Gao W, Korn T, Strom T, Oukka M . Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441(7090):235-8. DOI: 10.1038/nature04753. View

16.

Veldhoen M, Hocking R, Atkins C, Locksley R, Stockinger B . TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006; 24(2):179-89. DOI: 10.1016/j.immuni.2006.01.001. View

17.

Ciric B, El-Behi M, Cabrera R, Zhang G, Rostami A . IL-23 drives pathogenic IL-17-producing CD8+ T cells. J Immunol. 2009; 182(9):5296-305. DOI: 10.4049/jimmunol.0900036. View

18.

Wong C, Lit L, Shan Tam L, Li E, Wong P, Kei Lam C . Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol. 2008; 127(3):385-93. DOI: 10.1016/j.clim.2008.01.019. View

19.

Espinosa A, Dardalhon V, Brauner S, Ambrosi A, Higgs R, Quintana F . Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J Exp Med. 2009; 206(8):1661-71. PMC: 2722164. DOI: 10.1084/jem.20090585. View

20.

Kang H, Liu M, Datta S . Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells. J Immunol. 2007; 178(12):7849-58. DOI: 10.4049/jimmunol.178.12.7849. View